Advances in HIV/AIDS therapy

Advances in Internal Medicine

Volumn 45, Issue , 2000, Pages

  Johnson, Steven C ^a,b   Gerber, John G ^c  

^a Division of Infectious Diseases   (United States)

^b UNIVERSITY OF COLORADO HOSPITAL   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AIDS RELATED COMPLEX; ANTIBIOTIC RESISTANCE; DRUG COMBINATION; DRUG EFFECT; DRUG INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; QUALITY OF LIFE; REVIEW; VIRUS REPLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTIVIRAL AGENTS; DRUG INTERACTIONS; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; HIV; HIV INFECTIONS; HUMANS; QUALITY OF LIFE; VIRUS REPLICATION;

EID: 0033630647     PISSN: 00652822     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (121)

1. Centers for Disease Control and Prevention: HIV/AIDS Surveillance Report. Year-end Edition. 9(no. 2), 1998.
2. Karon JM, Rosenberg S, Mcquillan G, et al: Prevalence of HIV Infection in the United States, 1984 to 1992. JAMA 276:126-131, 1996.
3. Centers for Disease Control and Prevention: Update: Trends in AIDS Incidence. MMWR 46:861-867, 1997.
4. World Health Organization: 1998 HIV/AIDS Reports at www.who.org.
5. Ho DD, Neumann AU, Perelson AS, et al: Rapid turnover of plasma virions and CD4+ lymphocytes in HIV-1 infection. Nature 373:123-126, 1995.
6. Wei X, Ghosh SK, Taylor ME, et al: Viral dynamics in HIV-1 infection. Nature 373:117-122, 1995.
7. Havlir DV, Richman DD: Viral dynamics of HIV: Implications for drug development and therapeutic strategies. Ann Intern Med 124:984-994, 1996.
8. Pantaleo G, Graziosi C, Demarest JF, et al: HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 362:355-358, 1993.
9. Piatak M, Saag MS, Yang LC, et al: high levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 259:1749-1754, 1993.
10. Mellors JW, Kingsley LA, Rinaldo CR, et al: Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 122:573, 1995.
11. Mellors JW, Rinaldo CR, Gupta P, et al: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272:1167-1170, 1996.
12. Mellors JW, Munoz AM, Giorgi JV, et al: Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV infection. Ann Intern Med 126:946-954, 1997.
13. Buchbinder SP, Katz MH, Hessol NA, et al: Long-term HIV-1 infection without immunologic progression. AIDS 8:1123-1128, 1994.
14. Cao Y, Qin L, Zhang L, et al: Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type I infection. N Engl J Med 332:201-208, 1995.
15. Pantaleo G, Menzo S, Vaccarezza M, et al: Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med 332:209-216, 1995.
16. Michael NL, Chang G, Louis LG, et al: The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nat Med 3:338-340, 1997.
17. O'Brien WA, Hartigan PM, Martin D, et al: Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. N Engl J Med 334:426, 1996.
18. Katzenstein DA, Hammer SA, Hughes MD, et al: The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med 335:1091-1098, 1996.
19. Coffin JM: HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy. Science 267:483-489, 1996.
20. Larder BA, Kemp SD: Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine. Science 243:1731-1734, 1989.
21. Condra JH, Schleif WA, Blahy OM, et al: In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374:569-571, 1995.
22. Molla A, Korneyeva M, Gao Q, et al: Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Med 2:760-766, 1996.
23. Gunthard H, Wong J, Ignacio C, et al: Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J Virol 72:2422-2428, 1998.
24. Autran B, Carcelain G, Li TS, et al: Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 277:112-116, 1997.
25. Wong JK, Hezareh M, Gunthard H, et al: Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278:1291-1295, 1997.
26. Finzi D, Hermankova M, Pierson T, et al: Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278:1295-1300, 1997.
27. Saag MS, Holodniy M, Kuritzkes DR, et al: HIV viral load markers in clinical practice. Nature Med 2:625-629, 1996.
28. De Clercq ED: Antiviral therapy for human immunodeficiency virus infections. Clin Microbiol Rev 8:200, 1995.
29. Spooner KM, Lane HC, Masur H: Guide to major clinical trials of antiretroviral therapy administered to patients infected with human immunodeficiency virus. Clin Infect Dis 23:15-27, 1996.
30. Hammer SM, Katzenstein DA, Hughes MD, et al: A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 335:1081-1090, 1996.
31. Delta Coordinating Committee. Delta: A randomized double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 348:283-291, 1996.
32. Saravolatz LD, Winslow DL, Collins G, et al: Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. N Engl J Med 335:1099-1106, 1996.
33. Eron JJ, Benoit SL, Jemsek J, et al: Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N Engl J Med 333:1662, 1995.
34. Hammer SM, Squires KE, Hughes MD, et al: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 337:725-733, 1997.
35. Cameron DW, Heath-Chiozzi M, Danner S, et al: Randomized placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet 351:543-548, 1998.
36. Tashima K, Staszewski S, Stryker R, et al: A phase III, multicenter, randomized, open-label study to compare the antiretroviral activity of efavirenz (EFV) + indinavir (IDV) versus EFV + zidovudine (ZDV) + lamivudine (3TC) versus IDV + ZDV + 3TC at 48 weeks (Study DMP-266-006). Abstract LB16. Presented at the Sixth Conference on Retroviruses and Opportunistic Infections, Chicago, Jan 31-Feb 4, 1999.
37. Manion DJ, Labriola D, Ruiz N, et al: Efficacy of efavirenz (Sustiva) containing regimens in patients with baseline plasma HIV-RNA viral loads exceeding 100,000 copies/mL. Abstract 383. Presented at the Sixth Conference on Retroviruses and Opportunistic Infections, Chicago, Jan 31-Feb 4, 1999.
38. Staszewski S, Keiser P, Gathe J, et al: Ziagen/combivir is equivalent to indinavir/combivir in antiretroviral naive adults at 24 weeks (CAN 3005). Abstract 20. Presented at the Sixth Conference on Retroviruses and Opportunistic Infections, Chicago, Jan 31-Feb 4, 1999.
39. Mellors J, Lederman M, Haas D, et al: Durable activity of ziagen (Abacavir, ABC) combined with protease inhibitors (PI) in therapy naive adults. Abstract 625. Presented at the Sixth Conference on Retroviruses and Opportunistic Infections, Chicago, Jan 31-Feb 4, 1999.
40. Haubrich R: Phase 2 study of amprenavir, a novel protease inhibitor, in combination with ZDV/3TC. Abstract 12321. Presented at the World AIDS Conference, Geneva, Switzerland, June 28-July 4, 1998.
41. Wang LH, Delehanty J, Blum MR, et al: FTC: A potent and selective anti-HIV agent demonstrating desirable pharmacokinetic (PK) characteristics. Abstract 415. Presented at the 36th Annual Meeting of the Infectious Diseases Society of America, Denver, Nov 12-15, 1998.
42. Kahn J, Thompson M, Mildvan D, et al: Selection of FTC dose based on viral kinetics and pharmacokinetics in an accelerated clinical trial design. Abstract 12208. Presented at the 12th World AIDS Conference, Geneva, June 28-July 3, 1998.
43. Kahn J, Lagakos S, Weng D, et al: A multicentered, double-blind placebo controlled study of the efficacy and safety of adefovir when added to standard antiretroviral therapy. Abstract 1-108. Presented at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, Calif, Sept 24-27, 1998.
44. Myers RA, Blick G, Shepp D, et al: Randomized study of adefovir dipivoxil in combination with indinavir and reverse transcriptase inhibitors for treatment-naive HIV-infected patients. Abstract 1-107. Presented at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, Calif, Sept 24-27, 1998.
45. Deeks SG, Collier A, Lalezari J, et al: The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: A randomized, double-blind, placebo controlled trial. J Infect Dis 176:1517-1523, 1997.
46. Cherrington JM, Mulato AS, Lamy PD, et al: Adefovir dipivoxil (bis-POM PMEA) therapy significantly decreases HIV RNA in patients with high level AZT/3TC-resistant HIV. Abstract 1-84. Presented at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, Calif, September 24-27, 1998.
47. Fridland A, Robbins B, Rodman J, et al: Cellular pharmacology of the antiviral agents PMPA and PMEA in vitro and in vivo. Abstract 41175. Presented at the 12th World AIDS Conference, Geneva,June 28-July 3, 1998.
48. Foli A, Sogocio KM, Anderson B, et al: In vitro selection and molecular characterization of human immunodeficiency virus type I with reduced sensitivity to 9-[2-(phosphonomethoxy)ethyl] adenine (PMEA). Antiviral Research 32:91-98, 1996.
49. Mulato AS, Lamy PD, Miller MD, et al: Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy. Antimicrob Agents Chemother 42:1620-1628, 1998.
50. Miller M, Anton KE, Mulato AS, et al: HIV-1 expressing the 3TC-associated M184V mutation in reverse transcriptase shows increased sensitivity to adefovir and PMPA as well as decreased replication capacity in vitro. Abstract 41214. Presented at the 12th World AIDS Conference, Geneva, June 28-July 3, 1998.
51. Deeks SG, Barditchcrovo P, Lietman P, et al: Safety, pharmacokinetics, and antiviral activity of intravenous 9-[2-(R)-(phosphonomethoxy) propyl] adenine: A novel anti-human immunodecifiency virus (HIV) therapy, in HIV-infected adults. Antimicrob Agents Chemother 42:2380-2384, 1998.
52. Cundy KC, Safrin S, Coleman R, et al: Oral PMPA prodrug: Relationship between clinical pharmacokinetics, safety, and anti-HIV activity. Abstract 12211. Presented at the 12th World AIDS Conference, Geneva, June 28-July 3, 1998.
53. Miller M, Cherrington JM, Lamy PD, et al: Genotypic changes in HIV RT which develop during Preveon (adefovir dipivoxil) therapy do not decrease susceptibility to PMPA. Abstract 41218. Presented at the 12th World AIDS Conference, Geneva, June 28-July 3, 1998.
54. Sham H, Kempf D, Molla A, et al: Design, synthesis, and biological properties of ABT-378, a highly potent HIV protease inhibitor. Abstract 14. Presented at the Fourth Conference on Retroviruses and Opportunistic Infections, Washington, DC, Jan 22-26, 1997.
55. Korneyeva M, Chernyvskiy T, Norbeck D, et al: Virological evaluation of ritonavir-resistant virus to the HIV protease inhibitor ABT-378. Abstract 212. Presented at the Fourth Conference on Retroviruses and Opportunistic Infections, Washington, DC, Jan 22-26, 1997.
56. Carrillo A, Stewart KD, Sham HL, et al: In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor. J Virol 72:7532-7541, 1998.
57. Murphy R, King M, Brun S, et al: ABT-378/ritonavir therapy in antiretroviral-naive HIV-1 infected patients for 24 weeks. Abstract 15. Presented at the Sixth Conference on Retroviruses and Opportunistic Infections, Chicago, Jan 31-Feb 4, 1999.
58. Kilby JM, Hopkins S, Venetta TM, et al: Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 4:1302-1307, 1998.
59. Schrager LK, D'Souza MP: Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy. JAMA 280:67-71, 1998.
60. Havlir DV, Marschner IC, Hirsch MS, et al: Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. N Engl J Med 1998;339:1261-1268, 1998.
61. Pialoux G, Raffi F, Brun-Vezinet F, et al: A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. N Engl J Med 339:1269-1276, 1998.
62. Reijers MHE, Weverling GJ, Jurriaans S, et al: Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) Study. Lancet 352:185-190, 1998.
63. Demeter L, Hughes M, Fischl M, et al: Predictors of virologic and clinical responses to indinavir (IDV) + ZDV + 3TC or ZDV + 3TC. Abstract 509. Presented at the Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, Feb 1-5, 1998.
64. De Wolf F, Weverling G, Lukashov V, et al: Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy. Abstract 11156. Presented at the 12th World AIDS Conference, Geneva, June 28-July 4, 1998.
65. Lori F, Malykh A, Cara A, et al: Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science 266:801-805, 1994.
66. Lori F, Malykh A, Foli A, et al: Combination of a drug targeting the cell with drug targeting the virus controls human immunodeficiency virus type 1 resistance. AIDS Res Hum Retro-viruses 16:1403-1409, 1997.
67. Montaner JS, Zala C, Conway B, et al: A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus (HIV) disease receiving chronic didanosine therapy: Canadian HIV Trials Network Protocol 080. J Infect Dis 175:801-806, 1997.
68. Reutschmann OT, Opravil M, Iten A, et al: ddl + d4T +/- hydroxyurea for HIV-1 infection. Abstract # 656. Presented at the Fifth Conference on Retroviruses and Opportunistic Infections, February 1-5, Chicago, 1998.
69. Villa J, Nugier F, Bargues G, et al: Absence of viral rebound after treatment of HIV-infected patients with didanosine and hydroxycarbamide. Lancet 350:635-636, 1997.
70. Lori F, Jessen H, Clerici M, et al: Drugs suppressing HIV replication and cell proliferation decrease proviral DNA to undetectable levels. Abstract #LB11. Presented at the Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, Feb 1-5, 1998.
71. Chun TW, Engel D, Mizell S, et al: Effect of interleukin-2 in diminution of latently infected, resting CD4+ T cells in HIV-1 infected patients receiving highly active antiretroviral therapy. Abstract 496. Presented at the Sixth Conference on Retroviruses and Opportunistic Infections, Chicago, Jan 31-Feb 4, 1999.
72. Office of AIDS Research, National Institutes of Health: Report of the NIH Panel to Define Principles of Therapy of HIV Infection. Ann Intern Med 128 (No. 12, pt 2):1057-1078, 1998.
73. Department of Health and Human Services and the Henry J. Kaiser Family Foundation: Guidelines for the Use of Antiretroviral Agents in HIV-infected Adults and Adolescents. Revised May 5, 1999. Available at http://www.hivatis.com.
74. Carpenter C, Fischl M, Hammer S, et al: Antiretroviral therapy for HIV infection in 1998: Updated recommendations of the International AIDS Society - USA Panel. JAMA 280:78-86, 1998.
75. Gazzard B, Moyle G: 1998 Revision to the British HIV Association Guidelines for Antiretroviral Treatment of HIV Seropositive Individuals. Lancet 352:314-316, 1998.
76. Gulick RM, Mellors JW, Havlir D, et al: Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. JAMA 280:35-41, 1998.
77. Hecht FM, Grant RM, Petropoulos CJ, et al: Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med 339:307-311, 1998.
78. Kempf DJ, Rode RA, Xu Y, et al: The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS 12:F9-F14, 1998.
79. Kaufmann D, Pantaleo G, Sudre P, et al: CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Lancet 351:723-724, 1998.
80. Hirsch MS, Conway B, D'Aquila RT, et al: Antiretroviral drug resistance testing in adults with HIV infection. Implications for clinical management. JAMA 279:1984-1991, 1998.
81. Kinloch-De Loes S, Hirschel BJ, Hoen B, et al: A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med 333:408-413, 1995.
82. Rosenberg ES, Billingsley JM, Caliendo AM, et al: Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 278:1447-1450, 1997.
83. Connor EM, Sperling RS, Gelver R, et al: Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 331:1173-1180, 1994.
84. Wade NA, Birkhead GS, Warren BL, et al: Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med 339:1409-1414, 1998.
85. Centers for Disease Control and Prevention: Public Health Service Task Force Recommendations for the Use of Antiretroviral Drugs in Pregnant Women Infected with HIV-1 for Maternal Health and for Reducing Perinatal HIV-1 Transmission in the United States. MMWR 47(RR-2):1-30, 1998.
86. Mandelbrot L, Chenadec JL, Berrebi A, et al: Perinatal HIV-1 transmission: Interaction between zidovudine prophylaxis and mode of delivery in the French Perinatal Cohort. JAMA 280:55-60, 1998.
87. Cardo DM, Culver DH, Ciesielski CA, et al: A case-control study of HIV seroconversion in health care workers after percutaneous exposure. N Engl J Med 337:1485-1490, 1997.
88. Centers for Disease Control and Prevention: Public Health Service Guidelines for the Management of Health-Care Worker Exposures to HIV and Recommendations for Postexposure Prophylaxis. MMWR 47(RR-7):1-34, 1998.
89. D'Aquila RT, Johnson VA, Welles SL, et al: Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann Intern Med 122:401, 1995.
90. Schinazi RF, Larder BA, Mellors JW: Resistance table: Mutations in retroviral genes associated with drug resistance. Int Antiviral News 5:129-142, 1997.
91. Baxter J, Mayers D, Wentworth D, et al: A pilot study of the short-term effects of antiretroviral management based on plasma genotypic antiretroviral resistance testing (GART) in patients failing antiretroviral therapy. Abstract LB8. Presented at the Sixth Conference on Retroviruses and Opportunistic Infections, Chicago, Jan 31-Feb 4, 1999.
92. Chatta G, Arieff A, Cummings C, et al: Lactic acidosis complicating the acquired immunodeficiency syndrome. Ann Intern Med 118:37-39, 1993.
93. Roth VR, Kravcik S, Angel JB: Development of cervical fat pads following therapy with human immunodeficiency virus type 1 protease inhibitors. Clin Infect Dis 27:65-75, 1998.
94. Carr A, Samaras K, Chisholm DJ, et al: Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 351:1881-1883, 1998.
95. McDonald CK, Gerber JG: Drug prescribing practices in a university hospital HIV clinic. Abstract 190. Presented at the Fourth Conference on Retroviruses and Opportunistic Infections, Washington, DC, Jan 22-26, 1997.
96. Flexner C: HIV-protease inhibitors. N Eng J Med 338:1281-1292, 1998.
97. Woolley J, Studenberg S, Boehlert C, et al: Cytochrome P450 isozyme induction, inhibition, and metabolism studies with HIV protease inhibitor, 141W94. Abstract A60. Presented at the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Sept 28-Oct 1, 1997.
98. Hsu A, Granneman GR, Bertz RJ: Ritonavir: Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 35:275-291, 1998.
99. Jarvis B, Faulds D: Nelfinavir: A review of its therapeutic efficacy in HIV infection. Drugs 56:147-167, 1998.
100. Murphy R, Gagnier P, Lamson M, et al: Effect of nevirapine on pharmacokinetics of indinavir and ritonavir in HIV-1 patients. Abstract 374. Presented at the Fourth Conference on Retroviruses and Opportunistic Infections, Washington, DC, Jan 22-26, 1997.
101. Fiske, WD, Mayers D, Wagner K, et al: Pharmacokinetics of DMP 266 and indinavir in multiple oral doses in HIV-1 infected individuals. Abstract 568. Presented at the Fourth Conference on Retroviruses and Opportunistic Infections, Washington DC, Jan 22-26, 1997.
102. Fiske WD, Benedek IH, White SJ, et al: Pharmacokinetic interaction between efavirenz and nelfinavir mesylate in healthy volunteers. Abstract 349. Presented at the Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, Feb 1-5, 1998.
103. Borin MT, Chambers JH, Carel BJ, et al: Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate. Clin Pharmacol Ther 61:544-553, 1997.
104. Borin MT, Chambers JH, Carel BJ, et al: Pharmacokinetic study of the interaction between rifabutin and delavirdine mesylate in HIV infected patients. Antiviral Res 35:53-63, 1997.
105. Hoggard PG, Kewn S, Barry MG, et al: Effects of drugs on 2′,3′-dideoxy-2′,3′-didehydrothymidine phosphorylation in vitro. Antimicrob Agents Chemother 41:1231-1236, 1997.
106. Lavie A, Schlichting I, Vetter IR, et al: The bottleneck in AZT activation. Nat Med 3:922-924, 1997.
107. Havlir D, Friedland G, Pollard G, et al: Combination zidovudine and stavudine therapy versus other nucleosides: Report of two randomized trials (ACTG 290 and 298). Abstract 2. Presented at the Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, Feb 1-5, 1998.
108. Vogt MW, Hartshorn KL, Furman PA, et al: Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science 235:1376-1379, 1987.
109. Moore RD, Bartlett JG: Combination antiretroviral therapy in HIV infection: An economic perspective. Pharmacoeconomics 10:109-113, 1996.
110. Palella FJ, Delaney KM, Moorman AC, et al: Declining morbidity and mortality among patients with advanced himan immunodeficiency virus infection. N Engl J Med 338:853-860, 1998.
111. th World AIDS Conference, Geneva, June 28-July 3, 1998.
112. Powderly WG, Landay A, Lederman MM: Recovery of the immune system with antiretroviral therapy: The end of opportunism? JAMA 280:72-77, 1998.
113. Costagliola D, Salmon D, Michon C, et al: Recurrence of CMV disease in patients with a history of CMV retinitis receiving protease inhibitors. Abstract 22239. Presented at the 12th World AIDS Conference, Geneva, June 28-July 3, 1998.
114. Aberg JA, Yajko JM, Jacobson MA: Eradication of disseminated Mycobacterium avium complex (DMAC) in four patients after twelve months of anti-mycobacterial therapy and response to highly active antiretroviral therapy. Abstract 729. Presented at the Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, Feb 1-5, 1998.
115. Tural C, Sirera G, Romeu J, et al: A 24-month follow-up of cytomegalovirus retinitis without secondary prophylaxis following high-ly active antiretroviral therapy. Abstract 455. Presented at the Sixth Conference on Retroviruses and Opportunistic Infections, Chicago, Jan 31-Feb 4, 1999.
116. Jacobson MA, Zegans M, Pavan PR, et al: Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet 349:1443-1445, 1997.
117. Centers for Disease Control and Prevention: 1999 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus. MMWH Morb Mortal Wkly Rep 48(RR-10), 1999.
118. Schneider M, Borleffs J, Stolk R, et al: Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy. Lancet 353:201-203, 1999.
119. CDC. Recommendations of the Advisory Committee on Immunization Practices: Use of vaccines and immunglobulins in persons with altered immunocompetence. MMWR 42(RR4), 1993.
120. French M, Lenzo N, John M, et al: Immune restoration disease after treatment of immunodeficient HIV-infected patients with potent antiretroviral therapy. Abstract 22323. Presented at the 12th World AIDS Conference, Geneva, June 28-July 3, 1998.
121. Torriani F, Freeman W, Durand D, et al: Evidence that HAART induced immune recovery vitritis in CMV retinitis patients is immune mediated. Abstract 22240. Presented at the 12th World AIDS Conference, Geneva, June 28-July 3, 1998.